Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Comparison Of Post-Licensure Safety Surveillance Of 13-Valent Pneumococcal Conjugate Vaccine And 7-Valent Pneumococcal Conjugate Vaccine: Data From The Vaccine Advere Event Reporting System (Vaers), Jorge E. Arana
Public Health Theses
Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS).
Background: On February 24, 2010, Food and Drug Administration (FDA) licensed a 13-valent pneumococcal conjugate vaccine (Prevnar 13®, [PCV13]) for use among children aged 6 weeks--71 months. The Advisory Committee on Immunization Practices (ACIP) recommended PCV13 routine vaccination of all children aged 2--59 months, children aged 60--71 months with underlying medical conditions, with PCV13 replacing PCV7 for all doses.
Methods: We searched case reports to the Vaccine Adverse Event Reporting System (VAERS), a US …